Summary
The product Melanotan 2 (10 mg), manufactured by EOQ Remedies, underwent independent testing for authenticity and purity. The sample, identified by batch number VTS744, was submitted by EOQ Remedies and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the active ingredient Melanotan 2, with a concentration of 9.87 mg and a purity level of 99.574%.
The testing process began on 6 November 2024, with the sample received on 15 November 2024 and analysis completed on 18 November 2024. The results confirm the high purity of the sample, though independent validation through third-party testing is recommended for comprehensive product verification. This report aims to educate and promote harm reduction.
Detailed Report
Product Overview
- Manufacturer: EOQ Remedies
- Product Name: Melanotan 2 (10 mg)
- Active Ingredient: Melanotan 2
- Batch Number: VTS744
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #52844
- Testing Ordered: 6 November 2024
- Sample Received: 15 November 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: EOQ Remedies
- Analysis Paid For By: EOQ Remedies
Testing Results
- Specification: 10 mg (as stated on the label)
- Measured Concentration: 9.87 mg
- Purity: 99.574%
- Accuracy: 98.7% (slightly below the labeled claim)
Verification Details
- Verification URL: https://janoshik.com/tests/52844_J6KXPQEBEPDI
Evaluation of Reseller-Submitted Testing
This analysis confirms the high purity and near-accurate dosing of Melanotan 2 (10 mg) from EOQ Remedies. However, the testing was conducted on a sample submitted and funded by the manufacturer, which may introduce biases. Independent third-party validation across multiple batches would provide a more comprehensive assessment of product consistency and quality.
Conclusion
The analysis demonstrates that Melanotan 2 (10 mg) by EOQ Remedies contains 9.87 mg of the active ingredient with a high purity level of 99.574%. These findings underscore strong quality control for this batch but highlight the importance of additional independent testing for broader market assurance. This report is intended as an educational tool for informed decision-making.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
